Contact information
Research groups
Ricardo A. Fernandes
COI Group Leader
The main objective of our research group is to identify key functional aspects affecting anti-tumor responses by T cells. To do this, we use protein engineering, guided by structural and signaling information, to generate novel molecules that allow us to explore and interrogate key aspects of receptor signaling and T cell function. We are currently focusing our efforts in developing molecules to overcome “inhibitory” signaling by immune checkpoint receptors and to enhance signaling by the T-cell receptor.
Ricardo Fernandes recently joined CAMS Oxford Institute coming from Stanford where he developed novel molecules to effectively shut down signaling by immune receptors such as PD-1.
Recent publications
-
Can we predict T cell specificity with digital biology and machine learning?
Journal article
Hudson D. et al, (2023), Nature reviews. Immunology, 23, 511 - 521
-
Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides.
Journal article
Yang X. et al, (2022), Nature, 612, 771 - 777
-
Structure of a fully assembled tumor-specific T cell receptor ligated by pMHC.
Journal article
Sušac L. et al, (2022), Cell, 185, 3201 - 3213.e19
-
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM.
Journal article
Lanz TV. et al, (2022), Nature, 603, 321 - 327
-
Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
Journal article
Theruvath J. et al, (2022), Nature medicine, 28, 333 - 344